Latest News About Samsung Bioepis

Here’s the latest I can share about Samsung Bioepis based on recent public releases:

• SB3 trastuzumab biosimilar: The FDA accepted SB3 for review under the 351(k) pathway. If approved, Merck/MSD would handle U.S. commercialization. This marks Samsung Bioepis’ first oncology biosimilar candidate to enter U.S. regulatory review. [Source: Business Wire via Ritzau press release, 2026-02-25][2]

• SB5 adalimumab biosimilar: FDA accepted for review Samsung Bioepis’ SB5, a candidate referencing Humira, signaling continued progression of their immunology biosimilar portfolio in the U.S. market. [Source: Business Wire via Ritzau press release, 2025-04-01][1]

• Other activity: Samsung Bioepis has an ongoing pipeline that includes ophthalmology biosimilars (e.g., bevacizumab references) and additional immunology candidates, with frequent updates on regulatory progress, trial initiations, and market strategy across regions. Examples include prior phase 3 programs and regulatory activities in Europe and the U.S. noted in GlobeNewswire and corporate announcements. [Sources include GlobeNewswire listings and corporate news pages, 2024–2025][3][4][5]

If you’d like, I can:

• Pull the most current single-page summaries from Samsung Bioepis’ newsroom and provide a concise, dated timeline.
• Create a quick comparison table of SB3 vs SB5 in terms of target indication, regulatory status, and anticipated U.S. partner/launch details.
• Fetch more details on any specific biosimilar candidate (e.g., SB27, OPUVIZ) and summarize their regulatory or clinical status.

Would you like me to proceed with a focused summary on SB3 and SB5, or broaden to the full latest biosimilars pipeline?

Citations:

• SB3 FDA acceptance for review (SB3 vs trastuzumab)[2]
• SB5 FDA acceptance for review (adalimumab biosimilar)[1]
• Additional context on Samsung Bioepis’ pipeline and regulatory activity (GlobeNewswire and corporate pages)[4][5][3]